You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKesson
AstraZeneca
Johnson and Johnson
Harvard Business School

Last Updated: January 20, 2021

DrugPatentWatch Database Preview

Apotex Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for APOTEX, and what generic and branded alternatives to APOTEX drugs are available?

APOTEX has two hundred and sixty-six approved drugs.

There are twenty-three tentative approvals on APOTEX drugs.

Drugs and US Patents for Apotex

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc CELECOXIB celecoxib CAPSULE;ORAL 204197-003 Jun 2, 2015 AB RX No No   Start Trial   Start Trial
Apotex Inc ZOLPIDEM TARTRATE zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 200266-002 Sep 10, 2013 AB RX No No   Start Trial   Start Trial
Apotex Inc OLANZAPINE olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 091265-004 Oct 24, 2011 AB RX No No   Start Trial   Start Trial
Apotex Inc TEMOZOLOMIDE temozolomide CAPSULE;ORAL 204159-004 Jul 5, 2018 DISCN No No   Start Trial   Start Trial
Apotex TERIFLUNOMIDE teriflunomide TABLET;ORAL 209601-002 Nov 2, 2018 DISCN No No   Start Trial   Start Trial
Apotex FLUTICASONE PROPIONATE fluticasone propionate SPRAY, METERED;NASAL 208150-001 Feb 29, 2016 OTC No No   Start Trial   Start Trial
Apotex NEVIRAPINE nevirapine TABLET, EXTENDED RELEASE;ORAL 205258-001 Apr 3, 2014 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Apotex

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-004 Dec 29, 1992 6,172,233*PED   Start Trial
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-004 Dec 29, 1992 6,121,291*PED   Start Trial
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-002 Feb 16, 1999 6,080,759*PED   Start Trial
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-003 Dec 6, 2000 6,133,289*PED   Start Trial
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-002 Feb 16, 1999 7,229,640*PED   Start Trial
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-003 Dec 29, 1992 4,721,723*PED   Start Trial
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-002 Dec 29, 1992 5,872,132*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for APOTEX drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Suspension 10 mg/5 mL ➤ Subscribe 2005-02-10
➤ Subscribe Extended-release Tablets 37.5 mg ➤ Subscribe 2009-05-19
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 2005-09-09
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Medtronic
McKinsey
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.